Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): A two-stage randomised clinical trial in the Philippines

Acta Tropica

Volumn 75, Issue 1, 2000, Pages 39-52

  Quiambao, Beatriz P ^a   Lang, Jean ^b   Vital, Sabine ^b   Montalban, Cecilia G ^a   Le Mener, Valentine ^b   Wood, Susan C ^b   Miranda, Elizabeth ^a  

^a RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^b 58 Ave Leclerc BP 7046 69348 ^*  (France)

Author keywords

Efficacy; Post exposure treatment; Purified; Severe rabies exposure; Vero cell rabies vaccine

Indexed keywords

ANTIBODY; NEUTRALIZING ANTIBODY; PASTEUR ANTIRABIES SERUM; RABIES IMMUNOGLOBULIN; RABIES VACCINE; UNCLASSIFIED DRUG;

IMMUNIZATION; RABIES;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; PHILIPPINES; PROPHYLAXIS; RABIES; RANDOMIZED CONTROLLED TRIAL; RASH; SEROCONVERSION;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY; DOUBLE-BLIND METHOD; HORSES; HUMANS; IMMUNIZATION, PASSIVE; MIDDLE AGED; NEUTRALIZATION TESTS; PROSPECTIVE STUDIES; RABIES; RABIES VACCINES; RABIES VIRUS; VACCINES, COMBINED; VERO CELLS;

PHILIPPINES;

ANIMALIA; EQUIDAE; RNA VIRUSES;

EID: 0033981249     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(99)00092-3     Document Type: Article

References (32)

1. Atanasiu P. Quantitative assay and potency test of antirabies serum and immunoglobulin. Laboratory Techniques in Rabies (ch. 40). 3rd edn:1993;314-318 WHO, Geneva.
2. Chutivongse S., Supich C., Wilde H. Acceptability and efficacy of purified Vero-cell rabies vaccine in Thai children exposed to rabies. Asia Pacif. J. Publ. Health. 2:1988;179-184.
3. Chutivongse S., Wilde H., Supich S., Baer G.M., Fishbien D.B. Post-exposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet. 335:1990;896-898.
4. Chutivongse S., Wilde H., Fishbein B., Baer G., Hemachudha T. One-year study of the 2-1-1 intramuscular post-exposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine. 9:1991;573-576.
5. Corey L. Wilson J.D. Harrison's Principles of Internal Medicine. 14th edn:1998;1128-1129 McGraw-Hill, New York.
6. Fangtao L, Shubeng C, Yinzhon W. Use of serum and vaccine in combination for prophylaxis following exposure to rabies. Rev. Infect. Dis. 10(4):1988;766-770.
7. Fescgarek R. et al. Post-exposure rabies prophylaxis: when the guidelines are not respected. Vaccine. 9:1991;868-872.
8. Gross E.M., Bearnern J.E. Post-exposure rabies prophylaxis establishing effectiveness of abbreviated treatments. Vaccine. 3:1985;283.
9. Hatwick M.A.W., Gregg M.B. The disease in man. Baer G.M. The Natural History of Rabies. II:1975;281-304 Academic Press, New York.
10. Khawplod P., Wilde H., Chomckey P., Benjavongkulchai M., Yenmuang W., Chaiyabutr N., Sitprija V. What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously? Vaccine. 14:1996;389-391.
11. Lang J., Plotkin S.A. Rabies risk and immunoprophylaxis in children. Advances in Pediatric Infectious Diseases. 13th edn:1998;219-255 Mosby-Year Book.
12. Lang J., Cetre J.C., Picot N., Lanta M., Briantais P., Vital S., Le Mener V., Lutsch C., Rotivel Y. Immunogenicity and safety in adults of a new chromatographically purified Vero cell rabies vaccine (CPRV): a randomised, double-blind trial with purified Vero cell rabies vaccine (PVRV). Biologicals. 1998(26):1999;299-308.
13. Miranda, M.E.G., Miranda, N.L.J., Robles, C.G., Fishbien, D.B., 1994. Factors affecting decisions for rabies post-exposure management of dog bite patients. JAMA S.E. Asia, Proceedings to 4th WPCC, pp. 233-234.
14. Philippines Compendium of Animal Rabies Control, 1994. National Rabies Seminar Workshop, May 1994.
15. Plotkin S.A., Rupprecht C.E., Koprowski H. Rabies vaccine. Plotkin S., Orenstein W.A. Vaccines. 3rd edn:1999;743-766 Saunders, Philadelphia.
16. Schuirmann D.J. A comparison of two one-sided tests: procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharmaceut. 15:1987;657-680.
17. Seligmann E.B.J. The NIH test for potency. Kaplan H.M., Koprowski H. Laboratory Techniques in Rabies. 3rd edn:1973;279-286 World Health Organization, Geneva.
18. Siwasontiwat D., Lumlertdacha B., Polsuwan C., Hemachudha J., Chutivongse S., Wilde H. Rabies: is provocation of the biting dog relevant for risk assessment. Trans. R. Soc. Trop. Med. Hyg. 86:1992;443.
19. Smith J.S., Yager P.A., Baer G.M. A rapid tissue culture test for determining rabies neutralising antibodies. WHO Monogr. Ser. 23:1973;354-357.
20. Strady A., Lang J., Rotivel Y., Jaussaud R., Fritzell C., Tsiang H. L'immunoprophlyaxie de la rage: actualisation des recommendations. Presse Med. 25:1996;1023-1027.
21. Suntharasamai P., Warrell D.A., Warrell M.J. et al. New purified Vero-cell vaccine prevents rabies in patients bitten by rabid animals. Lancet. 2:1986;129-131.
22. Thongcharoen P., Wasi C., Sirikawin S., Chaiprasithkul P., Puthavatana P. Rabies and post-exposure prophylaxis in Thai children. Asian Pacif. J. Allerg. Immunol. 7:1989;41-46.
23. Vodpija I et al. An evaluation of second generation tissue-culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 post exposure schedule. Vaccine. 4:1986;245-248.
24. Vodpija I. et al. Interaction of rabies vaccine with human rabies immunoglobin and reliability of a 2-1-1 schedule application for post-exposure treatment. Vaccine. 6:1988;283-286.
25. Warrell D.A. Rhabdoviruses: rabies and rabies-related viruses. Weatherall D.J., Leadingham J.G.G., Warrell D.A. Oxford Textbook of Medicine. 2nd edn:1987;5.105-5.114 Oxford University Press, Oxford.
26. Wilde H., Choomkasien P., Hemachudha T. et al. Failure of rabies post-exposure treatment in Thailand. Vaccine. 7:1989;49-52.
27. Wilde H., Gluek R., Khawplod P., Cryz S.J., Tantawichien T., Thipkong P., Chomchey P., Prakongsri S., Beryavongkulchai M., Sumboonanondha A., Samranwetaya P., Supakorn K., Sitprija V. Efficacy study of a new albumin-free human diploid cell rabies vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients. Vaccine. 13:1995;593-595.
28. Wilde H., Sirikawin S., Sabchareon A., Kingnate D., Tantawichien T., Harischandra P.A.L., Chaiabutyr N., de Silva D.G.H., Fernando L., Liyanage J.B., Sitprija V. Failure of postexposure treatment of rabies in children. Clin. Infect. Dis. 22:1996;228-232.
29. Wilde H., Thipkong P., Phar B., Sitprija V., Chaiyabutr N. Heterologous antisera and antivenins are still essential biologicals: perspectives of a worldwide crisis. Ann. Intern. Med. 125:1996;233-236.
30. th Report., WHO Tech. Rep. Ser. 824, pp. 1-84.
31. World Health Organisation, 1995. Consultation on intradermal application of human rabies vaccines. Geneva 13-14 March, 1995; Weekly Epidemiol. Rec. 47, 336-337.
32. World Health Organisation, 1996. The World Health Report 1996. Fighting disease Fostering development. Geneva, pp. 57-58.